Nobivac Piro
vaccine against babesiosis in dogs
Table of contents
Overview
The marketing authorisation for Nobivac Piro has been withdrawn at the request of the marketing-authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Nobivac Piro
|
| Agency product number |
EMEA/V/C/000084
|
| Active substance |
|
| International non-proprietary name (INN) or common name |
vaccine against babesiosis in dogs
|
| Species |
Dogs
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI07AO
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Intervet International BV
|
| Revision |
4
|
| Date of issue of marketing authorisation valid throughout the European Union |
02/09/2004
|
| Contact address |
Wim de Körverstraat 35
5831 AN Boxmeer The Netherlands |
Product information
22/05/2013 Nobivac Piro - EMEA/V/C/000084 - R/0006
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals for canidae
Therapeutic indication
For active immunisation of dogs of six months of age or older against Babesia canis to reduce the severity of clinical signs associated with acute babesiosis (B. canis) and anaemia as measured by packed cell volume.
Onset of immunity: Three weeks after the basic vaccination course.
Duration of immunity: Six months after the last (re-)vaccination.